| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S382 R16397 |
Tomson (Carbamazepine), 2018 | Polydactyly | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 6.43 [0.31;134.02] C | 2/1,957 0/2,514 | 2 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5529 R16227 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Polydactyly | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.19 [0.09;54.89] C | 1/72 0/52 | 1 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6685 R18581 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Extra digits | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [3.40;4444.20] C excluded (control group) |
1/3 0/62 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6689 R18698 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Extra digits | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.39;576.73] C | 1/3 0/8 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 5.57 [0.84;36.88] | 4 | 2,032 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick) ; 3: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6685